UCB SA (OTCMKTS:UCBJY) Short Interest Update

UCB SA (OTCMKTS:UCBJY) saw a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 4,700 shares, a growth of 2,250.0% from the December 15th total of 200 shares. Based on an average daily trading volume, of 13,700 shares, the short-interest ratio is presently 0.3 days.

UCB Trading Down 0.4 %

Shares of OTCMKTS:UCBJY traded down $0.35 during trading on Monday, hitting $99.83. The company’s stock had a trading volume of 12,707 shares, compared to its average volume of 9,835. UCB has a fifty-two week low of $44.26 and a fifty-two week high of $100.66. The business has a 50 day moving average price of $96.70 and a two-hundred day moving average price of $90.41. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.